All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy
Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Read More
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
zacks.com
Read More
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company's internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research.
businesswire.com
Read More
Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab Limited is an innovative Pharma partnering with US and European Pharmas to secure approvals for, and market their drugs in China. ZLAB stock has surged over 105% in the past year, driven by strong revenue growth and ambitious plans for future drug launches. The company aims to achieve $2bn in annual revenues by 2028, with key drugs like Vyvgart and Cobenfy leading the charge.
seekingalpha.com
Read More
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
ZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China.
seekingalpha.com
Read More
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. “In China, cervical cancer is a serious health concern with approximately 150,000 new cases diagnosed annually1,”.
businesswire.com
Read More
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet
The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
Read More
Zai Lab Announces Participation in Investor Conferences in March 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in March 2025: Leerink Partners 2025 Global Healthcare Conference Fireside Chat: Monday, March 10, 2025, 9:20 a.m. EST Location: Miami, FL Jefferies Biotech on the Beach Summit Time: Tuesday, March 11, 2025 Location: Miami, FL A live webcast of the fireside chat will be available on th.
businesswire.com
Read More
Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Head of Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Michael Yee - Jefferies Yen-Der Li - Leerink Partners Reena Patel - Citi Linhai Zhao - Goldman Sachs Li Wang Watsek - Cantor Fitzgerald Po Han Lin - Morgan Stanley Operator Hello, ladies and gentlemen. Thank you for standing by and welcome to Zai Lab's Fourth Quarter and Full Year 2024 Financial Results Conference Call.
seekingalpha.com
Read More
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights and corporate updates. “2024 was a defining year for Zai Lab, marked by strong sales growth, financial strength, and significant pipeline progress. As we look ahead, 2025 is set to be a transformative year with VYVGART's continued momentum, three new product launches, progress with ZL-1310, and.
businesswire.com
Read More
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
Zai Lab Limited (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
Read More
Here's Why 'Trend' Investors Would Love Betting on Zai Lab Limited (ZLAB)
Zai Lab Limited (ZLAB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
zacks.com
Read More
Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade
The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
Read More
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website.
businesswire.com
Read More
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC). “Receiving an Orphan Drug Designation for ZL-1310 recognizes its potential to treat patients with SCLC. These patients have an urgent need for innovative treatment opt.
businesswire.com
Read More
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults. “There are more than 8 million patients living with schizophrenia in China who face significant unmet needs due to the limited efficacy and undesirable side effects of current treatment options,” said Dr. Rafael Amado, M.D., Presiden.
businesswire.com
Read More
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically meaningful improvement in overall survival with TIVDAK treatment for patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy. The China subpopulation results were consistent with those in the global population: TIVDAK demonstrate.
businesswire.com
Read More
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
BOSTON & SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and.
businesswire.com
Read More
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
SHANGHAI & CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and.
businesswire.com
Read More
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
SHANGHAI & SUZHOU, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink's TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. Through this collaboration, Zai Lab further expands its global oncology pipeline with anoth.
businesswire.com
Read More
Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
Zai Lab Limited is transitioning from a "Hold" to a "Buy" rating due to rapid revenue growth and upcoming potential approvals. ZLAB's strategy involves in-licensing U.S.-approved drugs for the Chinese market, with key products like Zejula, Qinlock, Nuzyra, Vyvgart, and Optune driving revenue. Despite high costs, ZLAB's consistent quarterly revenue growth and a strong cash position indicate a promising future.
seekingalpha.com
Read More
Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?
Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Read More
Zai Lab Announces Participation in Investor Conference in January 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conference in January 2025: 43rd Annual J.P. Morgan Healthcare Conference Presentation: Tuesday, January 14, 2025, 1:30 p.m. PST Location: San Francisco A live webcast of the presentation will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.com/webcasts-present.
businesswire.com
Read More
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally adv.
businesswire.com
Read More
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: AUGTYRO® (repotrectinib) is included in the NRDL for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC); NUZYRA® (omadacycline) is ren.
businesswire.com
Read More
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this collaboration, Zai Lab will leverage the industry-leading commercialization inf.
businesswire.com
Read More
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the anticipated closing of its previously announced underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. In addition, Zai Lab today announced that the underwriters in the offering fully exercis.
businesswire.com
Read More
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. The gross proceeds to Zai Lab from the offering, before deducting underwriting discounts and commissions and other offeri.
businesswire.com
Read More
Zai Lab Announces Proposed Public Offering of American Depositary Shares
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $200.0 million of American depositary shares (“ADSs”), each representing ten ordinary shares of the Company with a par value of $0.000006 per share. All ADSs will be offered by Zai Lab. Zai Lab expects to grant the underwriters a 30-day option to p.
businesswire.com
Read More
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics
The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Read More
Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado – President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citigroup Operator Hello, ladies and gentlemen. Thank you for standing by.
seekingalpha.com
Read More
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate updates. “In the third quarter, we delivered strong commercial results, maintained financial discipline, and continued to advance our global pipeline of innovative medicines,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “The launch of VYVGART® has been a.
businesswire.com
Read More
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CI.
businesswire.com
Read More
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company's Phase 3 multi-center trial evaluating the safety and efficacy of KarXT (xanomeline and trospium chloride) in China. Consistent with previous global studies, the registrational bridging trial met its primary endpoint, with KarXT demonstrating a statistically significant 9.2-point reduction in the Positive and Negative Syndrome Scale (PANSS) total sc.
businesswire.com
Read More
Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last?
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
zacks.com
Read More
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC), at the EORTC-NCI-AACR (ENA) Symposium 2024 in Barcelona, Spain, as an oral presentation during the plenary session. ZL-1310 is being tested in patients with previously treated extensive-stage Small Cell Lung Cancer (ES-SCLC) after at least one prior platinum-bas.
businesswire.com
Read More
Zai Lab Announces Participation in November and December Investor Conferences
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in November and December 2024: Goldman Sachs APAC Healthcare Corporate Day 2024 Time: November 5-8, 2024 Location: Hong Kong, Hong Kong Jefferies London Healthcare Conference Fireside Chat: Tuesday, November 19, 2024,1:30 p.m. GT Location: Aldwych, London Citi's 2024 Global Healthcare.
businesswire.com
Read More
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the Company's investigational DLL3-targeted antibody-drug conjugate (ADC), in patients with advanced stage small cell lung cancer (SCLC). The live conference call and webcast will take place on Thursday, October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT). Conference Call and Webcast Information Lis.
businesswire.com
Read More
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2024 and recent corporate updates, before the opening of the U.S. equity markets on Tuesday, November 12, 2024. The Company will host a live conference call and webcast on the same date, at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website.
businesswire.com
Read More
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a Phase 1 study of ZL-1310, the Company's investigational antibody-drug conjugate (ADC), will be presented during a plenary session at the EORTC-NCI-AACR Symposium (ENA) 2024 taking place October 23-25, in Barcelona, Spain. The preliminary results from the ongoing, open-label, multicenter clinical trial (NCT06179069) will address the potential of ZL-1310 as a novel.
businesswire.com
Read More
Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains?
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
zacks.com
Read More
Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025
Zai Lab Limited leverages global partnerships to commercialize approved therapies in China, focusing on oncology, autoimmune, infectious, and neurological conditions. ZLAB's leading products include VYVGART, AUGTYRO (Repotrectinib), and XACDURO, with VYVGART contributing significantly to Q2 2024 revenues. ZLAB is also developing wholly-owned IP, including ZL-1310 and ZL-1218, which could extend its global footprint beyond China.
seekingalpha.com
Read More
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a preclinical study of ZL-1503, the company's internally discovered IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (EADV) 2024 taking place September 25-28 in Amsterdam, Netherlands. The results will address the potentia.
businesswire.com
Read More
Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem
It's not often that a genuine hidden-gem candidate appears in the market. But that label might apply to Chinese biotechnology firm Zai Lab (NASDAQ: ZLAB ).
investorplace.com
Read More
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC), 1,000mg (5.6ml)/vial indicated as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine.
businesswire.com
Read More
Best Momentum Stocks to Buy for July 10th
KGC, ZLAB, and EAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 10, 2024.
zacks.com
Read More
New Strong Buy Stocks for July 10th
AY, APOG, KGC, ZLAB, and FNKO have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2024.
zacks.com
Read More
Aldinger Company Acquires J&J Calibrations
DALLAS--(BUSINESS WIRE)--Aldinger, a leader in calibration/metrology services, has acquired J&J Calibrations, enhancing its offerings and expanding its geographical footprint.
businesswire.com
Read More
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
SHANGHAI, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the second quarter of 2024 and recent corporate updates, after the closing of the U.S. equity markets on Tuesday, August 6, 2024. The Company will host a live conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the C.
businesswire.com
Read More
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume resp.
businesswire.com
Read More
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical trial (NCT06380907) evaluating the efficacy and safety of the company's internally developed anti-IL-17 investigational therapy, ZL-1102, for the treatment of chronic plaque psoriasis (CPP). ZL-1102 is a novel human VH antibody fragment (Humabody®) targeting the IL-17 cytokine. Emphasizing its unique approach, ZL-1102 is bein.
businesswire.com
Read More
Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
SolStock Deals and Financings Japan’s Takeda (TAK, OTCPK:TKPHF; TSE: 4502) acquired global rights to an Alzheimer’s therapy developed by AC Immune SA (ACIU) of Switzerland for $100 million upfront and up to $2.1 billion in milestone payments (see story). With the $100 million, Takeda owns an option to license AC Immune’s active immunotherapies that target toxic forms of amyloid beta (Abeta), including ACI-24.060. ACI-24.060 is an anti-Abeta active immunotherapy candidate aimed at reducing the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression. Currently, ACI-24.060 is being tested in a double-blind, placebo-controlled Phase Ib/II trial in subjects with mild Alzheimer’s disease and in adults with Down's syndrome. San Diego’s Erasca (ERAS) acquired rights for two China-developed pre-clinical RAS candidates in two separate agreements, while it is sidelining two of its own candidates and temporarily discontinuing development on a third candidate. Erasca will also raise $160 million from investors. The company acquired ex-China rights to a pan-RAS molecular glue (ERAS-0015) from Joyo Pharmatech of Guangzhou in a $189 million deal and global rights to a pan-KRAS inhibitor (ERAS-4001) from Sichuan Medshine Discovery in a $170 million agreement. Shenzhen Beimei Pharma acquired greater China rights for Twyneo, a therapy for acne vulgaris, from Israel’s Sol-Gel (SLGL) for $15 million. Sol-Gel will be eligible to receive up to $10 million in upfront and regulator milestones. The remaining $5 million is potential royalty payments. Twyneo is the only fixed-dose combination of tretinoin and benzoyl peroxide cream available in the US; it is approved to treat acne vulgaris in adults and pediatric patients. Beimei markets products for pediatrics patients with a portfolio of more than 40 drugs approved or in the pipeline. Trials and Approvals Shanghai’s Zai Lab (ZLAB; HK: 9688) reported China’s NMPA approved Augtyro (repotrectinib) as a treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) (see story). The approval is based on an open-label, single-arm, Phase I/II trial that evaluated repotrectinib in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC. In 2020, Zai Lab acquired China rights to the drug from Turning Point Therapeutics of San Diego for $25 million upfront and up to $151 million in milestones, plus royalties. Turning Point is now a division of Bristol-Myers Squibb (BMY). Shanghai Everest Medicines (HK: 1952) launched Nefecon, a treatment for IgA nephropathy (IgAN), in China by filling the first prescription. IgAN, a rare disease that accounts for 35-50% of glomerular disease cases in China, can cause end-stage renal disease that is treated by kidney replacement or dialysis. Nefecon is a targeted-release formulation of budesonide, a second-generation synthetic corticosteroid. In 2019, Everest acquired greater China rights to the drug from Calliditas Therapeutics (CALT, OTCPK:CLTEF) of Sweden in a $121 million agreement. Nefecon is already approved in the US and EU. Suzhou Ractigen Therapeutics reported that a China IND was approved for RAG-17 as a therapy for Amyotrophic Lateral Sclerosis (ALS). RAG-17 is a therapeutic siRNA designed to suppress the SOD1 gene in ALS patients with pathogenic mutations. Of the more than 50 genes associated with ALS, SOD1 gene mutations account for approximately 20% of the cases. Using Ractigen's proprietary SCAD delivery platform, RAG-17 combines siRNA with an accessory oligonucleotide to improve efficacy in central nervous system tissues. In preclinical studies, RAG-17 showed the ability to improve motor function and prolong survival. Beijing InnoCare Pharma (OTCPK:INCPF; HK: 09969; SHA: 688428) has completed the enrollment process in a China Phase II trial of ICP-488, a potential psoriasis therapy (see story). ICP-488 is a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor. The trial enrolled 129 patients who were randomized to one of three treatment groups in a 1:1:1 ratio: a 6mg once-daily group, a 9mg once-daily group, and a placebo group, for 12 consecutive weeks of treatment. By binding the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokines. Shanghai Mabwell (SHA: 688062) reported positive data from a China trial of its novel Nectin-4-targeting ADC for triple-negative breast cancer. In 20 patients with advanced or metastatic disease, 50% reported an objective response and 80% experienced disease control. One patient had a complete response that has continued for 20 months so far. Mabwell says a China IND for the drug, 9MW2821, has also been accepted in combination with an immune checkpoint inhibitor. According to the company, 9MW2821 is the first the Nectin-4-targeting ADC developed by a Chinese company to start clinical trials. Nanjing IASO Bio announced that Science Immunology, a sub-journal of Science, published a single-cell analysis of its anti-BCMA CAR T cell therapy in patients with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is an autoimmune disease that usually occurs in the optic nerve and spinal cord, though it can affect the brain. The disease, which occurs in flare-ups that can cause muscle weakness or blindness, is sometimes misdiagnosed as multiple myeloma. Last year, IASO and its partner, Innovent (OTCPK:IVBIY, OTCPK:IVBXF), were approved in China to launch Equecabtagene Autoleucel, an anti-BCMA CAR T drug, as a fourth-line therapy for multiple myeloma. Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.
https://seekingalpha.com
Read More
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
SHANGHAI & CAMBRIDGE, Mass. & WALTHAM, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus comp.
businesswire.com
Read More
Zai Lab Announces Participation in May and June Investor Conferences
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in May and June 2024: J.P. Morgan 20th Annual Global China Summit Panel Discussion: Thursday, May 23, 2024, 10:00 a.m. HKT Location: Shanghai, China Jefferies Global Healthcare Conference Fireside Chat: Wednesday, June 5, 2024, 3:30 p.m. ET in Track 2 Location: New York, New York Goldm.
businesswire.com
Read More
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the supplemental Biologics License Application (sBLA) for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The CDE granted priority review on May 11, 2024 and Breakthrough Thera.
businesswire.com
Read More
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). The approval is based on the pivotal TRIDENT-1 study, an open-label, single-arm, Phase 1/2 trial that evaluated repotrectinib in TKI-.
businesswire.com
Read More
Zai Lab Limited (ZLAB) Q1 2024 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson & Chief Executive Officer Josh Smiley - President & Chief Operating Officer Rafael Amado - President & Head-Global Oncology Research & Development Harald Reinhart - President & Head-Global Development, Neuroscience, Autoimmune & Infectious Diseases Yajing Chen - Chief Financial Officer Jonathan Wang - Chief Business Officer Conference Call Participants Anupam Rama - JPMorgan Louise Chen - Cantor Michael Yee - Jefferies Linhai Zhao - Goldman Sachs Yigal Nochomovitz - Citigroup Jonathan Chang - Leerink Partners Jack Lin - Morgan Stanley Operator Hello, ladies and gentlemen, thank you for standing by and welcome to Zai Lab's First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
seekingalpha.com
Read More
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of 2024 and recent corporate updates, after the closing of the U.S. equity markets on Wednesday, May 8, 2024. The Company will host a live conference call and webcast on Thursday, May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's webs.
businesswire.com
Read More
Zai Lab Statement on Executive Management Team's Agreement on Share Activities
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Executive Officers of Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, today announced that they have each agreed that they do not anticipate selling any shares in Zai Lab through the remainder of 2024, except for any shares in existing Rule 10b5-1 plans that are currently effective or to cover tax obligations associated with the vesting o.
businesswire.com
Read More
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California. The global oncology programs to be showcased at AACR 2024 include a Phase 1a/1b study of ZL-1310 (NCT06179069), a novel antibody-drug c.
businesswire.com
Read More
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) partner Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields (TTFields) therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cance.
businesswire.com
Read More
Shhh! 7 Small-Cap Stocks That Can Double by 2025
Small cap stocks like those discussed below tend to receive much less attention than their large cap competitors. Shares, which boast a market capitalization between $250 million and $2 billion, remain relatively small.
investorplace.com
Read More
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310, the company's global next-generation antibody-drug conjugate (ADC) program. The preclinical profile of ZL-1310 will be the focus of a poster presentation at the European Lung Cancer Congress 2024 (ELCC 2024), scheduled for March 20-23, 2024 in Prague, Czech Republic. ZL-1310 is a novel a.
businesswire.com
Read More
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the final overall survival (OS) data from the Phase 3 randomized, double-blind, placebo-controlled NORA study evaluating ZEJULA® (niraparib) in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC) will be shared in oral presentations at the 2024 Congress of the European Society of Gynaecological Oncology (ESGO), March 7-10, 2024, in Barcelona, Spain, and the 2024 So.
businesswire.com
Read More
Zai Lab Announces Participation in March Investor Conference
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conference in March 2024: Leerink Partners Global Biopharma Conference 2024 Presentation: Monday, March 11, 2024, 4:00 p.m. ET Location: Fontainebleau, Miami Beach Room: Glimmer 3 A live webcast of the presentation will be available on the Investor Relations page of Zai Lab's website at ir.zailabo.
businesswire.com
Read More
Zai Lab Limited (ZLAB) Q4 2023 Earnings Call Transcript
Zai Lab Limited (ZLAB) Q4 2023 Earnings Call Transcript
seekingalpha.com
Read More
Top 5 Health Care Stocks That Are Preparing To Pump In February - CNS Pharma (NASDAQ:CNSP), Biolase (NASDAQ:BIOL)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
benzinga.com
Read More
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the year ended December 31, 2023 and recent corporate updates, after the closing of the U.S. equity markets on Tuesday, February 27, 2024. The Company will host a live conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting.
businesswire.com
Read More
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced The New England Journal of Medicine (NEJM) has published data from the registrational Phase 1/2 TRIDENT-1 study evaluating repotrectinib (TPX-0005) in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancers (NSCLCs). Repotrectinib is a tyrosine kinase inhibitor (TKI) that has shown robust anti-tumor activity against ROS1+ cancers in preclinical models. In the TRIDENT-1 study,.
businesswire.com
Read More
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
Zai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Read More
Zai Lab Announces Participation in January Investor Conference
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conference in January 2024: J.P. Morgan 42nd Annual Healthcare Conference Presentation: Monday, January 8, 2024, 3:45 p.m. PST Location: San Francisco A live webcast of the presentation will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.com/webcasts-presentat.
businesswire.com
Read More
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: VYVGART® (efgartigimod alfa injection) is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR.
businesswire.com
Read More
Zai Lab Limited (ZLAB) Q3 2023 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Christine Chiou - Senior Vice President-Investor Relations Samantha Du - Founder, Chairperson & Chief Executive Officer Josh Smiley - President & Chief Operating Officer Rafael Amado - President & Head of Global Oncology and Research & Development Harald Reinhart - President & Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases Yajing Chen - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Yigal Nochomovitz - Citigroup Anupam Rama - JPMorgan Ziyi Chen - Goldman Sachs Operator Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's Third Quarter 2023 Financial Results Conference Call.
seekingalpha.com
Read More
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
SHANGHAI, China and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2023, along with recent product highlights and corporate updates.
globenewswire.com
Read More
Zai Lab Announces Participation in November Investor Conferences
SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in November 2023:
globenewswire.com
Read More
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
- Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET - Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET
globenewswire.com
Read More
Why Wall Street Thinks This Artificial Intelligence (AI) Stock Could Skyrocket 140% Over the Next 12 Months
This company uses AI to improve drug discovery for all of the 20 biggest biopharmaceutical companies. Even the most pessimistic analyst thinks the stock could jump nearly 32% over the next 12 months.
fool.com
Read More
Betting Big: 3 Tech Stocks Primed for a Breakout
The fervor around tech stocks to buy now has been palpable this year, with several household names reaching unprecedented heights. However, with such meteoric runs, many investors are left wondering which opportunities still hold genuine upside potential, especially in a market that seems, at times, overextended.
investorplace.com
Read More
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
SHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The Breakthrough Therapy Designation for efgartigimod SC was supported by data from both global and Chinese patients enrolled in the ADHERE study.
globenewswire.com
Read More
Zai Lab Stock: De-Risking Through Market Tapping
Zai Lab Limited is a biotech company that acts as a powerful partner for other biotechs to launch drug candidates in China. They currently distribute four drugs in mainland China and have a pipeline of cancer therapies awaiting approval. ZLAB has a strong financial position with significant cash reserves and potential for future sales growth.
seekingalpha.com
Read More
Why Shares of Zai Lab Limited Were Jumping on Tuesday
The company is collaborating with two other companies on a cervical cancer therapy. Zai Lab grew revenue by 45% year over year in the second quarter.
fool.com
Read More
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results
Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% announced that Tivdak, their treatment for cervical cancer, improved patients' overall survival in a late-stage study.
marketwatch.com
Read More
Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug
Zai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China.
zacks.com
Read More
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors
globenewswire.com
Read More
Zai Lab Announces Participation in September Investor Conferences
SHANGHAI, China and CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company's senior management team will participate in the following investor conferences in September 2023:
globenewswire.com
Read More
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
Read More
Zai Lab Limited (ZLAB) Q2 2023 Earnings Call Transcript
Zai Lab Limited. (NASDAQ:ZLAB ) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Christine Chiou - Senior Vice President of Investor Relations Yajing Chen - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Operating Officer Rafael Amado - President, Head of Global Oncology Research and Development Harald Reinhart - President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases Jonathan Wang - Chief Business Development Conference Call Participants Ziyi Chen - Goldman Sachs Yigal Nochomovitz - Citi Group Michael Yee - Jefferies Malcolm Kuno - JP Morgan Jonathan Chang - SVB Leerink Partners Jonathan Chang - SVB Securities Jason Liu - Credit Suisse Operator Hello, ladies and gentlemen.
seekingalpha.com
Read More
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
SHANGHAI, China and CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2023, along with recent product highlights and corporate updates.
globenewswire.com
Read More
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ: ZLAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
Read More
Zai Lab: LUNAR Trial Paves Way For New Therapies
Zai Lab Limited's recent clinical study results and partnerships demonstrate its commitment to innovation and product development, positioning it as a strong investment prospect in the pharmaceutical industry. The company's partnership with MediLink and the development of YL212, a next-generation antibody-drug conjugate, further strengthen its oncology pipeline and lung cancer product line. Despite a net loss, Zai Lab retains a substantial amount of cash and cash equivalents, short-term investments, and restricted cash, placing it in a strong position for further expansion and investment opportunities.
seekingalpha.com
Read More
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
Read More
Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
- Company to Host Conference Call and Webcast on August 8, 2023, at 8:00 a.m. ET - Company to Host Conference Call and Webcast on August 8, 2023, at 8:00 a.m. ET
globenewswire.com
Read More
JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
The Phase 3 PRIME study demonstrates that treatment with ZEJULA significantly extends progression-free survival versus placebo and reduces the risk of disease progression or death by 55% Findings confirm the benefit of ZEJULA monotherapy as first-line maintenance treatment, regardless of residual disease or biomarker status, in patients with newly diagnosed advanced ovarian cancer
globenewswire.com
Read More
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
SHANGHAI, China and CAMBRIDGE, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx SE (Euronext & Nasdaq: ARGX) today announced positive topline results from the ADHERE study evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint (p=0.000039), demonstrating a significantly lower risk of relapse with VYVGART Hytrulo compared to placebo. Detailed data from ADHERE will be presented at an upcoming medical meeting.
None
Read More
Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
SHANGHAI, China and CAMBRIDGE, Mass., July 14, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been treated in the mainland China portion of the global registrational, Phase 3 FORTITUDE-101 study for bemarituzumab, a potential first-in-class Fc-optimized monoclonal antibody that is designed to block fibroblast growth factors from binding and activating Fibroblast Growth Factor Receptor 2b (FGFR2b), inhibiting several downstream pro-tumor signaling pathways and potentially slowing tumor proliferation. FORTITUDE-101 is a global trial of bemarituzumab in first-line gastric cancer sponsored by Amgen.
globenewswire.com
Read More